What is d-mannose?

D-mannose is a simple sugar sold to prevent recurrent urinary tract infections. After absorption, some reaches the urine. In laboratory models, it can bind FimH, an adhesin on some Escherichia coli, and interfere with attachment to the urothelium. [4]

That mechanism does not predict clinical benefit by itself. In 2024, the largest double-blind trial assigned 598 women to approximately 2 g of d-mannose powder or fructose placebo each day for 6 months. It found no statistically significant reduction in the primary or secondary outcomes. [1]

Typical D-Mannose Protocols

No RDA, AI or UL exists for d-mannose. The 2 g daily amount is a trial exposure, not a nutrient requirement.

Episodes

Record symptoms, culture and clinical contact.

Dose

Record actual grams per day.

Context

Separate prevention from active infection.

Treatment

Keep antibiotics and other interventions.

What is d-mannose commonly used for?

The main commercial use is prevention of recurrent UTIs. Older open evidence created a positive signal, but the 2024 placebo-controlled trial directly tested that scenario in primary care and was negative. [1][2]

D-mannose should not replace diagnosis or treatment of an acute infection. Results from a product that also contains cranberry, probiotics or botanical extracts cannot establish what d-mannose did alone.

Which forms and labels matter?

Powder can reproduce the 2 g amount used in both major trials. A capsule may contain only 500 mg, so capsule count depends on the mass per unit. Combination products make benefits and adverse effects harder to attribute.

Compare d-mannose per serving, scoop size, other ingredients, lot and claims. A urinary-support label is not proof of prevention or treatment.

What does the human evidence show?

Hayward and colleagues randomized 598 women aged 18 or older with recurrent UTIs across 99 UK centres. Primary-outcome data were available for 583. At 6 months, 150/294 (51.0%) with d-mannose and 161/289 (55.7%) with placebo contacted ambulatory care for a suspected UTI. Relative risk was 0.92 (95% CI 0.80 to 1.05), and no secondary outcome differed significantly. [1]

Kranjčec and colleagues had earlier assigned 308 women, after antibiotic treatment of acute cystitis, to d-mannose 2 g, nitrofurantoin 50 mg or no prophylaxis for 6 months. Recurrences were lower in both active groups, but the trial was open and had no placebo. [2]

The 2022 Cochrane review included seven trials and 719 participants. Preparations, populations and comparators differed enough to prevent meta-analysis; the principal estimates had very low certainty. [3]

The 2025 AUA/CUA/SUFU amendment says clinicians should inform patients that d-mannose alone may not be effective for prophylaxis. That language reflects the large null trial without claiming that no individual can observe variation. [5]

How might d-mannose work?

FimH adhesins at the tips of type 1 fimbriae help selected uropathogenic bacteria attach to mannosylated residues on the urothelium. Free d-mannose can occupy those binding sites in adhesion models. [4]

The mechanism is specific to a proposed bacterial interaction; it does not kill bacteria, treat every uropathogen or overcome the most robust clinical test. Biological plausibility and efficacy in people are separate levels of evidence.

What are the risks and interactions?

Trials mainly report diarrhoea, digestive discomfort or vaginal burning, but adverse-event reporting was limited in older studies. In the 2024 trial, 28 serious adverse events occurred, 20 with d-mannose and 8 with placebo; none was judged related to the intervention. [1][3]

Extra caution is reasonable with diabetes, kidney disease, pregnancy, breastfeeding or a congenital glycosylation disorder. Formal medicine-interaction data and safety beyond 6 months remain poorly defined.

Regulatory status in the United States and Canada

D-mannose is sold as a dietary supplement in the United States and may appear in natural health products in Canada. Regulatory commercial status is not authorization to treat a UTI.

What should be monitored?

Record grams, formulation, timing, hydration, symptoms, temperature, flank pain, urine culture, antibiotics and clinical contact. The useful endpoint is the frequency of confirmed or medically attended episodes, not an isolated impression after one dose.

What happens after stopping?

No withdrawal syndrome or taper is established. Continue monitoring recurrences and do not automatically attribute an episode to stopping.

How should it be stored?

Keep powder dry, closed, away from heat and out of children’s reach. Use a defined scoop rather than a variable kitchen spoon.

Community experiences

Someone may associate fewer symptoms with d-mannose, but recurrences vary naturally and antibiotics, hydration and cultures also change. A prospective record helps separate a quiet period from a reliable effect.

How does d-mannose compare with other approaches?

Cranberry, increased water intake in low-volume drinkers, methenamine hippurate, postmenopausal vaginal estrogen and antibiotic prophylaxis each have distinct evidence and risks. The 2025 AUA/CUA/SUFU amendment places d-mannose among options whose effectiveness should be presented cautiously. [5]

A strategy depends on infection type, cultures, age, pregnancy, kidney function and recurrence pattern. It is not a simple swap of a supplement for an antibiotic.

Frequently asked questions

Does d-mannose prevent recurrent UTIs?

The best available trial found no statistically significant reduction over 6 months. [1]

Why did older findings look better?

The Kranjčec trial was open, lacked placebo and began after initial antibiotic treatment; its setting and bias risk differed. [2]

Is 2 g daily recommended?

It is a research protocol, not a personal recommendation. It was ineffective in the 2024 trial. [1]

Can it treat an active infection?

No solid evidence supports delaying assessment, culture or indicated treatment.

What do fever or flank pain mean?

They can signal upper-tract or systemic involvement and require prompt assessment.

Are combination products equivalent?

No. Adding cranberry, probiotics or extracts changes the product and prevents attribution to d-mannose alone.

Glossary

Terms used in this guide.

Recurrent UTI

Repeated episodes meeting defined clinical criteria.

FimH

Bacterial adhesin that can recognize mannose motifs.

Urothelium

Cellular lining of the urinary tract.

Risk difference

Absolute difference between proportions in two groups.

Prophylaxis

Intervention intended to prevent a future episode.

How this guide was researched

This guide prioritizes the large Hayward trial, the open Kranjčec trial, the Cochrane review, a FimH mechanism review and the 2025 AUA/CUA/SUFU amendment. PubMed identities and correction fields were checked October 9, 2026.

How this guide was made

Sources

Related guides